+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Company Analysis: Regeneron

  • Company Profile

  • 53 Pages
  • January 2021
  • Citeline
  • ID: 5357321
The publisher explores Regeneron’s prescription pharmaceutical performance and outlook over 2019-29.


  • Overview - Regeneron’s prescription pharmaceutical business has solid near-term growth but will see a long-term decline due to Eylea biosimilars.
  • Key themes - [1] Eylea sales will peak in 2022 as biosimilar competition begins in the US in 2023 [2] Collaboration revenue will continue to grow, driven by Dupixent and international Eylea sales.

Model updates (6 November 2020)

  • Eylea forecast adjusted higher due to strong rebound in sales
  • REGN-COV2 added to forecast.

Model updates (5 August 2020)

  • Eylea forecast adjusted lower due to COVID-19 impact
  • Libtayo forecast adjusted lower due to sales trends.

Model updates (5 May 2020)

  • Praluent forecast added due to restructuring of Sanofi agreement
  • Libtayo forecast adjusted higher due to recent trial data from non-small cell lung cancer and basal cell carcinoma.

Model updates (6 February 2020)

  • Eylea forecast adjusted higher due to continued share gains.

Table of Contents

Company Background
  • Company Overview
  • Key Metrics
  • SWOT Analysis
  • Key Drug & Company Information
  • Company Comparison

Recent Earnings Review
  • Earnings Overview
  • Pharma Insights Analysis

Company Forecast
  • Prescription Pharmaceuticals Sales Outlook
  • Branded Drug Outlook
  • Launch Profile Outlook
  • Therapy Area Outlook
  • Regional Sales Outlook
  • Lifecycle Analysis

Company Profile
  • Marketed & Pipeline Drugs
  • Recent Events & Analyst Opinions
  • Upcoming Catalysts
  • Recent Insights

Clinical Trial Overview
  • Clinical Trial Snapshot
  • Clinical Trials by Country
  • Clinical Trials by Status and Phase
  • Clinical Trials by Drug